CDKN2A and neoplasm: PDAC tumour PANC17 had satisfactory tumour content (74%) but presented with wild‐type KRAS G12/G13, in addition to no loss of CDKN2A, TP53 or SMAD4. Sanger sequencing failed to resolve the presence of G12/G13 mutation in two specimens with lower tumour contents, where sufficient DNA was available.